drugset / Trial / NCT03908372

Optimized Treatment Strategies for Early and Medium Stage Nasopharyngeal Carcinoma

NCT03908372

Phase 2/3 Unknown 120 enrolled Chinese Academy of Medical Sciences
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to optimize treatment strategies for patients with stage II and III nasopharyngeal carcinoma, reduce the side effects related to treatment and improve the quality of life.

Timeline

Start
2019-06-15
Primary completion
2021-05
Completion
2025-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Cisplatin Other / unclassified 75 mg/m2 Intravenous
Subject Cisplatin Other / unclassified 100 mg/m2 Intravenous
Subject Docetaxel Small molecule 75 mg/m2 Intravenous